Cytokinetics, Inc.

Astellas Pharma Gmbh

University of California

Global Blood Therapeutics, Inc.

Jeffrey Warrington

Bradley Paul Morgan

Scott E Collibee

Pu-Ping Lu

Chihyuan Chuang

Gustave Bergnes

Xiangping Qian

Alex R Muci

Zhe Yang

Luke W Ashcraft

Antonio Romero

Jeff Gardina

Hiroaki Tanaka

Fady Malik

Takashi Kamikubo

Masanori Miura

Tomoyuki Saito

Susumu Yamaki

Ippei Sato

Yuji Matsushima

Yasuhiro Shiina

Kayoko Mihara

Marc Andrew Garard

Munemichi Ohe

Hiroshi Kiyohara

Brian Walter Metcalf

Kumar Paulvannan

Matthew P Jacobson

Lan Hua

Matthew Jacobson

Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Tetrahydroisoquinoline derivatives

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Amino-pyrimidine skeletal muscle modulators

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Substituted pyridazines as skeletal muscle modulators

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, X, Z, Z, Z, Zand m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use

Certain heterocycles, compositions thereof, and methods for their use

Certain amino-pyrimidines, compositions thereof, and methods for their use

Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation

Growing community of inventors

San Mateo, CA, United States of America

Jeffrey Warrington